STOCK TITAN
  1. Home
  2. News
  3. BWAY

Brainsway Ltd. American Depositary Shares - BWAY STOCK NEWS

Welcome to our dedicated page for Brainsway Ltd. American Depositary Shares news (Ticker: BWAY), a resource for investors and traders seeking the latest updates and insights on Brainsway Ltd. American Depositary Shares stock.

BrainsWay Ltd. (NASDAQ & TASE: BWAY) is a leading global neurostimulation company headquartered in Jerusalem and the U.S., specializing in advanced noninvasive treatments for mental health disorders. With its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) technology, BrainsWay has revolutionized the field of brain disorder treatment, offering hope to millions of patients worldwide.

The company's innovative solutions target major depressive disorder (MDD), obsessive-compulsive disorder (OCD), and smoking addiction. BrainsWay's Deep TMS is FDA-cleared for its efficacy in treating these conditions. Clinical trials are ongoing for additional indications, including various psychiatric, neurological, and addiction disorders, aiming to expand the reach of this cutting-edge technology.

BrainsWay's treatments are non-invasive, safe, and convenient, typically requiring only brief daily sessions over a few weeks. This approach has already treated over 10,000 patients, delivering significant improvements without long-term side effects. The company leases and sells its Deep TMS systems, generating revenue while expanding its global footprint.

Recent collaborations, such as the partnership with Katie’s Way for providing mental health care to U.S. servicemembers, veterans, and their families, highlight BrainsWay's commitment to addressing critical mental health needs. This partnership underscores the transformative impact of Deep TMS technology in treating depression, particularly within the military community, where mental health issues are on the rise.

BrainsWay has also achieved significant milestones, such as being the first TMS company to receive three FDA-clearances for different indications, backed by pivotal clinical studies. The company's financial health is robust, with a reported 37% year-over-year revenue growth in the first quarter of 2024 and positive net income for consecutive quarters.

Looking ahead, BrainsWay continues to pursue innovations, including a clinical trial comparing accelerated Deep TMS protocols with standard treatments. This trial aims to enhance the convenience and appeal of Deep TMS, potentially broadening its market reach.

For more information about BrainsWay and its latest news, visit the company's website or follow their updates on StockTitan.

News

BrainsWay Reports Fourth Quarter and Full-Year 2023 Financial Results and Operational Highlights

Rhea-AI Summary
BrainsWay Ltd. (BWAY) reported record revenues in Q4 2023 with a 50% year-over-year growth, achieving positive net income. The company provided a revenue guidance of $37-$40 million for full-year 2024, showcasing continued profitability and cash generation. BrainsWay's financial and operational highlights included increased revenues, improved gross margins, positive operating income, net income, and Adjusted EBITDA. The company also expanded its Deep TMS installed base, collaborated with mental health providers, and enhanced reimbursement trends. BrainsWay's CEO highlighted the strong performance in 2023, anticipating revenue growth in 2024 and positioning the company as a leader in the TMS industry.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
earnings
-
News

BrainsWay to Report Fourth Quarter and Full Year 2023 Financial Results on March 6, 2024

Rhea-AI Summary
BrainsWay Ltd. (BWAY) announces the reporting of its Q4 and full year 2023 financial results and operational highlights on March 6, 2024. The Company will host a conference call to discuss the results and provide business updates.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.86%
Tags
conferences earnings
-
News

BrainsWay Initiates Clinical Evaluation of Rotational Field “Deep TMS 360°™” Technology

Rhea-AI Summary
BrainsWay Ltd. (BWAY) to clinically evaluate innovative stimulation technology in two new feasibility trials. The patented 'Rotational Field' TMS aims to stimulate a greater number of neurons in the brain, potentially impacting patients with stroke and obsessive-compulsive disorder (OCD). The technology is not yet FDA-cleared, but the company aims to assess its potential clinical impact in the new studies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.3%
Tags
none
News

BrainsWay Highlights Expanded Deep TMS™ Access with Growing Western U.S. Network

Rhea-AI Summary
BrainsWay Ltd. (NASDAQ & TASE: BWAY) announced increased collaboration with a growing mental health treatment provider in the Western US. The provider will receive seven Deep Transcranial Magnetic Stimulation (Deep TMS™) systems, with plans for further expansion. BrainsWay aims to improve access to non-drug mental health treatments for depression, OCD, and smoking addiction.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.48%
Tags
none
-
News

BrainsWay Announces Continued Expansion of Deep TMS™ in South Korea

Rhea-AI Summary
BrainsWay Ltd. (NASDAQ & TASE: BWAY) announced expanded availability of its Deep Transcranial Magnetic Stimulation (Deep TMS™) technology in South Korea. Recent sales are expected to bring BrainsWay’s installed base in the country to over 20 Deep TMS systems. The company's CEO, Hadar Levy, expressed satisfaction with the increasing traction of their state-of-the-art technology in South Korea, emphasizing its positive impact on mental health patients. The Deep TMS system, delivered through a patented coil design, is capable of stimulating important neural networks in the brain. BrainsWay’s unique therapeutic solution is currently cleared in South Korea to treat major depressive disorder.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.68%
Tags
none
-
News

Louisiana Insurer Expands Deep TMS™ Access for 1.9 Million Covered Lives

Rhea-AI Summary
BrainsWay Ltd. (NASDAQ & TASE: BWAY) Announces Blue Cross Blue Shield of Louisiana's Policy Update on Transcranial Magnetic Stimulation (TMS) Eligibility Criteria
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.89%
Tags
none
News

BrainsWay Reports Third Quarter 2023 Financial Results and Operational Highlights

Rhea-AI Summary
BrainsWay Ltd. (NASDAQ & TASE: BWAY) reported a robust 61% year-over-year revenue growth in Q3 2023, achieving breakeven operating income, positive Adjusted EBITDA, and cash flow from operations exceeding $1 million. The company also provided an operational update, highlighting significant financial and operational achievements, including revenue growth, gross margin stability, and expansion of Deep TMS technology in various countries. BrainsWay's CEO expressed confidence in the company's performance and future prospects, emphasizing strong revenue growth and cost optimization measures.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.87%
Tags
earnings
-
News

Clinical TMS Society Publishes First Coverage Recommendations for the Treatment of Smoking Addiction

Rhea-AI Summary
BrainsWay Ltd. announced that the Clinical TMS Society has published coverage recommendations for smoking addiction treatment using TMS. BrainsWay Deep TMS is the only TMS technology FDA-cleared for smoking addiction. The coverage guidance recommends TMS for individuals with Tobacco Use Disorder who failed two alternative treatments or have comorbid medical conditions. Results from BrainsWay's trial showed that over 25% of highly addicted smokers quit with Deep TMS treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.3%
Tags
none
-
News

BrainsWay to Report Third Quarter 2023 Financial Results on November 15, 2023

Rhea-AI Summary
BrainsWay Ltd. will report its third quarter 2023 financial results and operational highlights on November 15, 2023. The company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.24%
Tags
conferences earnings
News

BrainsWay Announces Presentation of Two Deep TMS™ Posters at Upcoming World Congress of Psychiatry

Rhea-AI Summary
BrainsWay announces preliminary research on late-life depression and accelerated depression treatment protocol to be featured at World Congress of Psychiatry. Results show promising response and remission rates in elderly patients using Deep TMS. Accelerated treatment regimen also shows comparable outcomes to traditional protocols. Research could potentially assist in expanding current labeling for Deep TMS.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.51%
Tags
none

FAQ

What is the current stock price of Brainsway Ltd. American Depositary Shares (BWAY)?

The current stock price of Brainsway Ltd. American Depositary Shares (BWAY) is $9.24 as of December 20, 2024.

What is the market cap of Brainsway Ltd. American Depositary Shares (BWAY)?

The market cap of Brainsway Ltd. American Depositary Shares (BWAY) is approximately 169.9M.

What does BrainsWay Ltd. do?

BrainsWay Ltd. specializes in noninvasive neurostimulation treatments for mental health disorders using its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) technology.

What conditions does BrainsWay's technology treat?

BrainsWay's Deep TMS technology treats major depressive disorder, obsessive-compulsive disorder, and smoking addiction. Additional indications are under clinical trials.

Is BrainsWay's treatment FDA-approved?

Yes, BrainsWay's Deep TMS technology has received FDA clearance for treating major depressive disorder, obsessive-compulsive disorder, and smoking addiction.

How safe is BrainsWay's treatment?

BrainsWay's treatment is non-invasive, with no systemic or long-term side effects. It typically involves brief daily sessions over a few weeks.

What are BrainsWay's recent achievements?

BrainsWay recently reported a 37% year-over-year revenue growth and positive net income for consecutive quarters. They also expanded their collaboration with Katie’s Way to provide mental health treatment to military personnel.

Where is BrainsWay headquartered?

BrainsWay is headquartered in Jerusalem, Israel, and has offices in the U.S., specifically in Burlington, MA.

How many patients have been treated with BrainsWay's technology?

Over 10,000 patients have been treated with BrainsWay's Deep TMS technology worldwide.

What is Deep TMS?

Deep TMS stands for Deep Transcranial Magnetic Stimulation, a non-invasive neurostimulation method used to treat various mental health disorders.

What is the future outlook for BrainsWay?

BrainsWay is focused on expanding its clinical indications and improving its treatment protocols. They anticipate continued strong financial performance and are actively pursuing additional clinical trials for new applications of their technology.

How can I get more information about BrainsWay?

For the latest news and information about BrainsWay, visit their official website or follow updates on financial news platforms like StockTitan.

Stock BWAY logo
Brainsway Ltd. American Depositary Shares

Nasdaq:BWAY

BWAY Rankings

#4001 Ranked by Market Cap
N/A Ranked by Dividends

BWAY Stock Data

169.88M
16.17M
19.22%
0.23%
Medical Devices
Healthcare
Link
United States of America
Jerusalem